The primary goals of the research proposed are to improve medical care, prolong patient survival with optimal achievement in quality of life, and rapidly assimilate data from clinical trials performed within the framework of the efforts of the Eastern Cooperative Oncology Group. Our approach to patient care is enhanced by extensive and organized involvement in additional disciplines; such cooperation is designed to provide patients with neoplastic disease the most promising therapy available. Although we are new members to the Eastern Group, our ultimate contribution can best be anticipated by reflecting on our past record in the Southeastern Cancer Study Group: Indiana University led the SECSG in the accrual of patients on multimodality protocols, and our leadership role was further defined by our achieving the highest patient accession rate within the group for its last two funded years and the exceptional administrative and participatory involvement in committee and protocol responsibilities by our faculty. Our 1987 patient accession total is not reflective of our future accrual rate with ECOG. Of necessity, we are competing scientifically important studies which were begun during our tenure with the SECSG. Of particular note are the extensive small cell lung cancer study (LUN 302) and our investigation of standard versus double dose chemotherapy for testis cancer (GU 303). Both protocols have strong accrual, 94 patients in all. These patient populations will become an additional resource for ECOG studies when LUN 302 and GU 303 have been completed, no later than May 1989. Yet another patient population will become available when our Veterans Administration Hospital completes its Institutional Assurance with the OPRR. Support for both ongoing and new research conducted by Indiana University will enable us to expand our leadership responsibilities within the Eastern Cooperative Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA049883-04
Application #
3558875
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1989-05-01
Project End
1994-04-30
Budget Start
1992-05-01
Budget End
1993-04-30
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Cohee, Andrea A; Bigatti, Silvia M; Shields, Cleveland G et al. (2018) Quality of Life in Partners of Young and Old Breast Cancer Survivors. Cancer Nurs 41:491-497
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Schneider, Bryan P; Shen, Fei; Gardner, Laura et al. (2017) Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clin Cancer Res 23:43-51
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Cohee, Andrea A; Adams, Rebecca N; Fife, Betsy L et al. (2017) Relationship Between Depressive Symptoms and Social Cognitive Processing in Partners of Long-Term Breast Cancer Survivors. Oncol Nurs Forum 44:44-51
Cohee, Andrea A; Adams, Rebecca N; Johns, Shelley A et al. (2017) Long-term fear of recurrence in young breast cancer survivors and partners. Psychooncology 26:22-28
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16

Showing the most recent 10 out of 87 publications